Amnon Schlegel, MD, PhD
Potential Financial Conflicts of Interest: None disclosed.
Schlegel A.; The Dry Pipeline of Antiarrhythmic Therapies. Ann Intern Med. 2005;142:871. doi: 10.7326/0003-4819-142-10-200505170-00017
Download citation file:
Published: Ann Intern Med. 2005;142(10):871.
TO THE EDITOR:
Zimetbaum and Josephson (1) are confident that “new approaches to drug development and screening for risk for adverse events may ultimately reduce the toxicity of [antiarrhythmic] agents.” Unfortunately, this optimism has fallen on deaf ears in the pharmaceutical industry: The only “new” drugs to treat atrial fibrillation are dofetilide, ibutilide, and azimilide (2, 3). These class III antiarrhythmic agents, far from being bold breakthroughs in the management of atrial fibrillation, are “niche” players (2) whose long-term efficacy and toxicity are matters of speculation (3).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only